AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 2023311 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 · USD | FY20232023-12-31 · CNY | FY20222022-12-31 · CNY |
|---|---|---|---|
| Income statement | |||
| Revenue | $134.35M | 221.98M | 209.71M |
| Cost of revenue | $3.98M | 30.54M | 22.00M |
| Gross profit | $130.36M | 191.44M | 187.71M |
| R&D expense | $129.77M | 706.97M | 743.10M |
| Interest expense | $8.83M | 96.06M | 52.78M |
| Pretax income | -$54.15M | -932.86M | -887.17M |
| Income tax | $1.43M | -7.15M | -4.25M |
| Net income | -$55.54M | -925.64M | -882.92M |
| EPS (basic) | -0.18 | -3.28 | -3.35 |
| EPS (diluted) | -0.18 | -3.28 | -3.35 |
| Balance sheet | |||
| Cash & equivalents | $122.35M | 1.04B | 1.35B |
| Receivables | $11.39M | 145.89M | — |
| Inventory | $904,000 | 16.17M | — |
| Current assets | $201.96M | 1.34B | — |
| PP&E, net | $116.37M | 905.82M | — |
| Goodwill | $3.38M | 24.69M | — |
| Total assets | — | — | — |
| Current liabilities | $159.82M | 934.17M | — |
| Short-term debt | $106.73M | 616.40M | — |
| Long-term debt | $121.85M | 1.18B | — |
| Total debt | $228.58M | 1.80B | — |
| Total liabilities | $321.08M | 2.43B | — |
| Shareholders' equity | $36.19M | 60.42M | 408.66M |
| Net debt | $106.23M | 757.55M | — |
| Shares outstanding | 315.22M | 290.20M | — |
| Cash flow statement | |||
| Operating cash flow | -$15.26M | -726.08M | -653.91M |
| Capital expenditure | $3.33M | 46.11M | 203.29M |
| Free cash flow | -$18.58M | -772.18M | -857.20M |
| Investing cash flow | -$49.60M | 21.92M | -384.61M |
| Financing cash flow | $43.12M | 368.75M | 619.27M |
| Stock-based compensation | $2.87M | 31.50M | 22.11M |
| Share buybacks | — | 5.92M | 26.78M |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.